Stockreport

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases [Seeking Alpha]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF Investing Group Leader Follow Play 10min Summary Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior [Read more]